Stockreport

Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating [Seeking Alpha]

Axsome Therapeutics, Inc.  (AXSM) 
Last axsome therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: axsome.com
PDF Q2 2025 saw 72% YoY revenue growth, driven by Auvelity and Sunosi, with improving margins and narrowing net losses. AXSM faces risks from competition, regulatory hurd [Read more]